Q2 2019 13F Holders as of 30 Jun 2019
-
Type / Class
-
Equity / Ordinary Shares, par value NIS 0.01 per share
-
Shares outstanding
-
46,239,275
-
Total 13F shares
-
14,675,395
-
Share change
-
+1,253,051
-
Total reported value
-
$526,992,234
-
Put/Call ratio
-
38%
-
Price per share
-
$35.94
-
Number of holders
-
83
-
Value change
-
+$44,822,103
-
Number of buys
-
51
-
Number of sells
-
31
Institutional Holders of UroGen Pharma Ltd. - Ordinary Shares, par value NIS 0.01 per share (URGN) as of Q2 2019
As of 30 Jun 2019,
UroGen Pharma Ltd. - Ordinary Shares, par value NIS 0.01 per share (URGN) was held by
83 institutional
shareholders
that filed Form 13F with the SEC.
Together, they reported ownership of
14,675,395 shares.
The largest 10 holders included
MENORA MIVTACHIM HOLDINGS LTD., Consonance Capital Management LP, WELLINGTON MANAGEMENT GROUP LLP, BlackRock Inc., HIGHLINE CAPITAL MANAGEMENT, L.P., Wildcat Capital Management, LLC, FMR LLC, CREDIT SUISSE AG/, MEITAV DASH INVESTMENTS LTD, and Clal Insurance Enterprises Holdings Ltd.
This page lists
83
institutional shareholders reporting positions in this security
for the Q2 2019 filing period.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price
|
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.